Plandai Biotechnology, Inc. Announces Favorable Results for Human Clinical Trial
March 20 2014 - 9:35AM
Marketwired
Plandai Biotechnology, Inc. Announces Favorable Results for Human
Clinical Trial
Phytofare(TM) Catechin Complex Delivers "Statistically
Significant" Anti-Aging Benefits
SEATTLE, WA--(Marketwired - Mar 20, 2014) - Plandaí
Biotechnology, Inc. (OTCQB: PLPL), a producer of highly
bioavailable plant extracts for industries including health,
wellness, nutraceutical, and pharmaceutical, today announced
favorable results from a recent human clinical trial involving a
topical preparation of its Phytofare™ Catechin Complex. The study,
which was undertaken by Prof. Banie Boneschans, North West
University in Potchefstroom, South Africa, one of the leading
research universities on the continent, was a double-blind study
that tested the anti-aging properties of Phytofare. Specifically,
the trial tested surface parameters (scaling and roughness), skin
hydration, and skin elasticity.
The results, which were released to the company on March 17,
stated that Phytofare yielded "statistically significant" results
when compared to a baseline product. The trial involved 35
female Caucasian test subjects who applied two topical creams
daily, the only difference being that one contained Phytofare™, to
skin patches which were tested at 14, 28, and 42 days.
The process of aging has a direct impact on the status of
the skin surface. Skin imperfections, such as wrinkles and
scaliness, reflect light differently than smooth, younger skin. A
UVA-light camera with a black-and-white video sensor was used to
photograph the skin surface and then measured the differences in
texture. The study showed that the addition of Phytofare™ improved
skin roughness by as much as 15% at 28 days, and a reduction in
scaliness of the stratum corneum by 20%. Both of these
measures were deemed "statistically significant" by the
researcher.
In testing skin hydration, a Corneometer® was used to measure
the change in the dielectric constant due to skin surface
hydration. The study showed the Phytofare increased skin
hydration by 15% at both 28 and 42 days, compared to .9% and 7.8%
for the base product. The study pointed out that skin
hydration improved significantly at 28 days and then maintained
that level throughout the study.
The elastic properties reflect the skin's ability to return to
its initial position after deformation and can be effected by
chronological- and photo aging of the skin. Skin elasticity was
evaluated by means of a Cutometer®. The study showed an
average improvement in skin elasticity of 1% at 42 days, though
there was significant inter subject variation which rendered the
results inconclusive with a recommendation for a larger sample size
and longer duration for a future study.
Plandaí Vice President Jamen Shively commented, "This study
validates the last decade of research and illustrate the benefits
of enhanced bioavailability. We envision our Phytofare™
topical formulation serving as the backbone for a host of potential
cosmetic products and look forward to sharing the results with our
distribution partners as we near release of Phytofare to the
market."
The company has placed an abstract of the study on its website:
www.plandaibiotech.com.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly
bioavailable, phytonutrient rich extracts which are being utilized
to deliver a new family of drugs to safely and affordably treat a
multitude of diseases and conditions. Plandaí Biotechnology
controls every aspect of the process, from growing the raw
materials on its farms in South Africa, to producing its patented
Phytofare™ extracts in-house, allowing the Company to guarantee the
continuity of supply as well as quality control throughout the
entire process. Targeted industries for the Company's products
include beverage, cosmeceutical, wellness, nutraceutical,
anti-aging, and pharmaceutical. For more information, please
visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements
and involve risks and uncertainties. Results, events and
performances could vary from those contemplated. These statements
involve risks and uncertainties which may cause actual results,
expressed or implied, to differ from predicted outcomes. Risks and
uncertainties include product demand, market competition, and
Plandaí's ability to meet current or future plans. Investors should
study and understand all risks before making an investment
decision. Readers are recommended not to place undue reliance on
forward-looking statements or information. Plandaí is not obliged
to publicly release revisions to any forward-looking statement, to
reflect events or circumstances afterward, or to disclose
unanticipated occurrences, except as required under applicable
laws.
Contact: Andrew Beyer Phone: 619-202-7456
Email: investor@Plandaíbiotech.com
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Sep 2023 to Sep 2024